Indicated for: endogenous Cushing syndrome
Route of administration: oral
Substance: metirapone (steroidogenesis inhibitor)
ATC: V04CD01 (Various | Other diagnostic agents | Tests for pituitary function)
Metyrapone is a cortisol synthesis inhibitor used for the diagnosis of adrenal insufficiency and the treatment of Cushing's syndrome. It works by inhibiting the enzyme 11-beta-hydroxylase, reducing cortisol production.
The medication is taken orally, usually in divided doses, with the dose adjusted based on the patient's response and hormone levels. Common side effects include nausea, vomiting, abdominal pain, and dizziness.
Metyrapone is contraindicated in patients with hypersensitivity to the active substance or severe hepatic impairment. Its use also requires careful monitoring of adrenal function and blood pressure.
This medication is an important option for diagnosing and managing adrenal disorders, helping to improve patients' quality of life.